Georgina Meneses-Lorente

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi An evaluation of a low-density DNA microarray using cytochrome P450 inducers
    Georgina Meneses-Lorente
    Merck Sharp and Dohme Neuroscience Research Center, Terling Park, Harlow, Essex, CM20 2QR, United Kingdom
    Chem Res Toxicol 16:1070-7. 2003
  2. ncbi A proteomic investigation of drug-induced steatosis in rat liver
    Georgina Meneses-Lorente
    Merck Sharp and Dohme Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, United Kingdom
    Chem Res Toxicol 17:605-12. 2004
  3. ncbi A quantitative high-throughput trapping assay as a measurement of potential for bioactivation
    Georgina Meneses-Lorente
    Department of Medicinal Chemistry Drug Metabolism Section, Merck Sharp and Dohme Research Laboratories, Harlow, Essex CM20 2QR, UK
    Anal Biochem 351:266-72. 2006
  4. ncbi N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists
    Jason M Elliott
    Department of Medicinal Chemistry, Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
    Bioorg Med Chem Lett 16:5748-51. 2006
  5. ncbi Multiplex proteomic analysis by two-dimensional differential in-gel electrophoresis
    Michael R Knowles
    Neuroscience Research Centre, Merck, Sharp and Dohme Research Laboratories, Harlow, Essex CM20 2QR, UK
    Proteomics 3:1162-71. 2003
  6. ncbi Utility of long-term cultured human hepatocytes as an in vitro model for cytochrome p450 induction
    Georgina Meneses-Lorente
    Department of Medicinal Chemistry Drug Metabolism Section, Merck Sharp and Dohme Research Laboratories, Harlow, Essex, United Kingdom
    Drug Metab Dispos 35:215-20. 2007
  7. ncbi N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II
    Jason M Elliott
    Department of Medicinal Chemistry, Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
    Bioorg Med Chem Lett 16:5752-6. 2006
  8. ncbi Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray
    Francoise de Longueville
    Laboratory of Biochemistry and Cellular Biology, University of Namur, rue de Bruxelles, Namur, Belgium
    Biochem Pharmacol 64:137-49. 2002

Detail Information

Publications8

  1. ncbi An evaluation of a low-density DNA microarray using cytochrome P450 inducers
    Georgina Meneses-Lorente
    Merck Sharp and Dohme Neuroscience Research Center, Terling Park, Harlow, Essex, CM20 2QR, United Kingdom
    Chem Res Toxicol 16:1070-7. 2003
    ..These results suggest that the Rat HepatoChip microarray may provide a fast and effective tool for assessing the toxicity profile of developmental drug candidates during the drug discovery process...
  2. ncbi A proteomic investigation of drug-induced steatosis in rat liver
    Georgina Meneses-Lorente
    Merck Sharp and Dohme Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, United Kingdom
    Chem Res Toxicol 17:605-12. 2004
    ....
  3. ncbi A quantitative high-throughput trapping assay as a measurement of potential for bioactivation
    Georgina Meneses-Lorente
    Department of Medicinal Chemistry Drug Metabolism Section, Merck Sharp and Dohme Research Laboratories, Harlow, Essex CM20 2QR, UK
    Anal Biochem 351:266-72. 2006
    ..This newly developed screen has proved to be specific, sensitive, robust, and a powerful tool for assessing bioactivation potential...
  4. ncbi N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists
    Jason M Elliott
    Department of Medicinal Chemistry, Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
    Bioorg Med Chem Lett 16:5748-51. 2006
    ..In an ex vivo assay in gerbil, the lead compound 2g occupies receptors within the CNS following oral dosing (Occ(90) 30 mg/kg po; plasma Occ(90) 0.95 microM) and has good selectivity and promising PK properties...
  5. ncbi Multiplex proteomic analysis by two-dimensional differential in-gel electrophoresis
    Michael R Knowles
    Neuroscience Research Centre, Merck, Sharp and Dohme Research Laboratories, Harlow, Essex CM20 2QR, UK
    Proteomics 3:1162-71. 2003
    ..The results illustrate the power of this multiplex proteomics technology and illustrate how proteomics can be used to understand gene function...
  6. ncbi Utility of long-term cultured human hepatocytes as an in vitro model for cytochrome p450 induction
    Georgina Meneses-Lorente
    Department of Medicinal Chemistry Drug Metabolism Section, Merck Sharp and Dohme Research Laboratories, Harlow, Essex, United Kingdom
    Drug Metab Dispos 35:215-20. 2007
    ..The use of long-term cultured hepatocytes on 96-well plates has proven to be sensitive, robust, and convenient for assessing P450 induction potential of new compound entities during the drug discovery process...
  7. ncbi N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II
    Jason M Elliott
    Department of Medicinal Chemistry, Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
    Bioorg Med Chem Lett 16:5752-6. 2006
    ..The lead compound (8m) occupies receptors within the CNS following oral dosing (Occ(90) 7 mg/kg po; plasma Occ(90) 0.4 microM) and has good selectivity and excellent PK properties...
  8. ncbi Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray
    Francoise de Longueville
    Laboratory of Biochemistry and Cellular Biology, University of Namur, rue de Bruxelles, Namur, Belgium
    Biochem Pharmacol 64:137-49. 2002
    ..Apoptosis-related genes have shown to be changed due to PB and PCN treatment, which confirms results from previous work...